Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
July 21, 2022 07:00 ET
|
Skye Bioscience, Inc.
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the...
Skye Bioscience Updates Phase 1 Timeline
July 20, 2022 07:00 ET
|
Skye Bioscience, Inc.
San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
June 07, 2022 07:00 ET
|
Skye Bioscience, Inc.
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE...
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
May 12, 2022 09:05 ET
|
Skye Bioscience, Inc.
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 ...
Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
May 05, 2022 07:00 ET
|
Skye Bioscience, Inc.
San Diego, California, May 05, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
April 28, 2022 07:00 ET
|
Skye Bioscience, Inc.
San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
March 03, 2022 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
February 16, 2022 08:30 ET
|
Skye Bioscience, Inc.
Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanoemulsion expected in the second quarter of 2022 SAN DIEGO, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB:...
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
February 01, 2022 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
January 10, 2022 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...